Journal of Hepatology
Journal
-
- Overview
-
- Identity
-
- View All
-
Overview
publication venue for
-
Characteristics and sustained virologic response of persons reporting illicit substance use in the past 6 months: Results from the CANUHC prospective patient registry
2019
-
GS-03-Global real world evidence of sofosbuvir/velpatasvir as a simple, effective regimen for the treatment of chronic hepatitis C patients: Integrated analysis of 12 clinical practice cohorts
2019
-
THU-179-Never too old to be direct acting antiviral treated for hepatitis C virus
2019
-
THU-393-HCV infection in Canadian immigrants: Characteristics and treatment outcomes of the CANUHC cohort
2019
-
Z-PROFILE: Real-world utilization and effectiveness of elbasvir/ grazoprevir in adult patients with chronic hepatitis C in Canada
2018
-
Real-world utilization of the new fixed-dose combination elbasvir/grazoprevir in adult patients with chronic hepatitis C in Canada: Z-PROFILE study
2017
-
Ledipasvir/Sofosbuvir with Ribavirin for 12 Weeks is Effective and Safe in Treatment-Naïve Genotype-3 Hepatitis C-Infected Patients in Canada
2016
-
Long Term Outcome of Splanchnic Vein Thrombosis in Cirrhosis
2016
-
P0128 : Low testosterone levels are associated with sarcopenia in cirrhotic patients
2015
-
P378 BENEFICIAL EFFECT OF THE PROBIOTIC VSL-3 ON LIVER INJURY-ASSOCIATED SICKNESS BEHAVIOR DEVELOPMENT BY ALTERING SYSTEMIC IMMUNITY AND INHIBITING ACTIVATED MONOCYTES FROM ENTERING THE BRAIN
2014
-
1141 BOCEPREVIR OR TELAPREVIR IN COMBINATION WITH PEGINTERFERON FOR HEPATITIS C GENOTYPE 1 INFECTION: AN INDIRECT COMPARISON META-REGRESSION ANALYSIS
2012
-
131 JX-594, A TARGETED MULTI-MECHANISTIC ONCOLYTIC POXVIRUS, IS WELL-TOLERATED AND EXHIBITS ANTI-TUMOR ACTIVITY IN PATIENTS WITH PRIMARY LIVER CANCER AND LIVER METASTASES
2011
-
310 CHROMATIN DYNAMICS OF GENES REPRESSION IN RESPONSE TO IFNa REVEAL NEW ROLES FOR STAT2, PHOSPHO-STAT2, HISTONE DEACETYLASES (HDACS) AND HISTONE METHYLATION MARKS
2011
-
124 RANDOMIZED PHASE II CLINICAL TRIAL OF INTRATUMORAL INJECTION OF JX-594, A TARGETED MULTI-MECHANISTIC ONCOLYTIC POXVIRUS, IN PATIENTS WITH HEPATOCELLULAR CARCINOMA
2010
-
55 HEMODYNAMIC EFFECTS AND SAFETY OF ONE-MONTH SIMVASTATIN TREATMENT IN PATIENTS WITH CIRRHOSIS AND PORTAL HYPERTENSION. A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED MULTICENTER TRIAL
2008
-
631 CHROMATIN-BASED ANALYSIS REVEALS THE COMPLEXITY OF THE ALPHA-IFN/STAT2 TRANSCRIPTOME AND IDENTIFIES FUNCTIONALLY DISTINCT SUBSETS OF STAT2 DIRECT TARGET GENES
2008
-
925 GLUCOCORTICOSTEROIDS FOR ALCOHOLIC HEPATITIS
2008
-
593 Treating chronic hepatitis C with peginterferon alpha-2a (40KD) (PEGASYS®) plus ribavirin in routine clinical practice: Factors predicting SVR using multiple logistic regression analysis
2006
-
Cannabidiolic acid (CBDA) regulates energy homeostasis and protects against non-alcoholic fatty liver disease (NAFLD) in mice.
78:S762-S762.
2023
-
Mitochondrial transplantation attenuates murine in vivo hepatic ischemia/reperfusion injury.
77:S822-S823.
2022
-
Reply to: “Real-world experience of serial serum levels of GS-331007 in chronic hepatitis C hemodialysis patients during and after sofosbuvir/velpatasvir therapy”.
75:1007-1008.
2021
-
Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis.
71:660-665.
2019
-
Screening for hepatitis C in Ontario, Canada: Exploring antibody positivity in the federal and provincial correctional systems.
68:S192-S192.
2018
-
P734 A SYSTEMATIC REVIEW OF INTERVENTIONS TO REDUCE ALCOHOL CONSUMPTION AMONG INDIVIDUALS WITH CHRONIC HCV INFECTION.
60:S314-S315.
2014
-
Global burden of alcoholic liver diseases.
59:160-168.
2013
-
The novel immunoregulatory molecule FGL2: A potential biomarker for severity of chronic hepatitis C virus infection.
53:608-615.
2010
-
Insulin prevents liver damage and preserves liver function in lipopolysaccharide-induced endotoxemic rats.
42:870-879.
2005
-
An intraluminal lesion in the mid-common bile duct and right hepatic duct causing right portal vein obstruction.
41:1060-1060.
2004
-
Randomised controlled double-blind trial of the calcium channel antagonist amlodipine in the treatment of acute alcoholic hepatitis.
28:194-198.
1998
-
Biological and clinicopathological features associated with hepatitis C virus type 5 infections.
24:109-113.
1996
-
Is sinusoidal portal hypertension a necessary factor for the development of hepatic ascites?.
16:249-250.
1992
has subject area
Identity
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)